Integrating Drug Product and Clinical Testing: 15 Years of Delivering Efficiency in Early Drug Development
Milano, Italy | 9 October 2024Join us for our seminar taking place during CPhI Milan.
Integration is important to advance all drugs through development and has been represented in industry structure since pharma companies were first formed. However, traditional drug product and clinical development disciplines remain separate. This results in significant CMC burden and a complex supply chain to move a drug product from manufacture into clinical testing.
Additionally, drug candidates are getting more difficult to synthesise and harder to formulate whilst clinical pressures to reach the key proof of concept (POC) milestone drive development teams to seek acceleration wherever possible.
Learn about the Quotient Sciences' Translational Pharmaceutics® platform.
To overcome these challenges, Quotient Sciences' Translational Pharmaceutics® platform integrates formulation development, on demand drug product manufacture, and clinical testing to provide horizontal integration that can help accelerate early drug development.
In this presentation, we describe the benefits of the Translational Pharmaceutics® platform, with real examples from our body of experience of over 500 programs of how it can be applied to solve drug development challenges.
Date 9th October - Agenda |
|---|
| Registration: 5.30PM - 6:00PM |
| Seminar: 6.15PM - 7.00PM |
| Drinks & Networking: 7.00PM - 9.00PM |
*This is an in person event that will not be recorded. A virtual option to attend is not available.
**We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.